Omniome, Inc., a San Diego, CA-based developer of an innovative DNA sequencing platform, raised an additional $60m with the completion of its Series C financing.
The round was led by Madrone Capital Partners. Current investors include ARCH Venture Partners, Decheng Capital, Domain Associates, Biomatics Capital Partners, Altitude Life Sciences Ventures, Nan Fung Life Sciences and others.
The company, which had raised $60m in financing in mid-2018, will utilize the new capital to expand its capabilities by hiring new team members across multiple disciplines, particularly in manufacturing, engineering, development, customer support and commercial, continue to optimize its proprietary technology and accelerate instrument development and delivery of commercially-impactful sequencing platforms.
Led by Dave Mullarkey, President and CEO, and Ken Song, M.D., Executive Chairman, Omniome is developing a breakthrough DNA sequencing platform capable of delivering high sequencing accuracy with the potential to advance cancer diagnostics, drive high fidelity single-cell applications and support clinical sequencing.